31656-77-6

Basic information

• Product Name: 1-(2-cyanophenyl)triaza-1,2-dien-2-ium
• CAS NO: 31656-77-6
• Molecular Formula: C₇H₄N₄
• Molecular Weight: 145.1409
• Mol File: 31656-77-6.mol
• Article Data: 24

Chemical Properties

• CAS DataBase Reference: 1-(2-cyanophenyl)triaza-1,2-dien-2-ium(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-cyanophenyl)triaza-1,2-dien-2-ium(31656-77-6)
• EPA Substance Registry System: 1-(2-cyanophenyl)triaza-1,2-dien-2-ium(31656-77-6)

Safety Data

• Hazardous Substances Data: 31656-77-6(Hazardous Substances Data)

Usage

General Description

1-(2-cyanophenyl)triaza-1,2-dien-2-ium is a chemical compound with an aromatic ring that contains a cyano group (–CN) attached to a phenyl group. It also features a triaza-1,2-dien-2-ium moiety, which consists of a five-membered ring with three nitrogen atoms and a double bond. 1-(2-cyanophenyl)triaza-1,2-dien-2-ium can be utilized in various chemical reactions and processes, including as a reagent in organic synthesis and as a building block in the preparation of pharmaceuticals and agrochemicals. Its unique structure and properties make it an important tool in the field of chemistry.

Upstream product

• 138642-62-3 2-Cyanophenylboronic acid 
• 4648-54-8 trimethylsilylazide 
• 2042-37-7 o-cyanobromobenzene 
• 612-24-8 o-nitrobenzonitrile 
• 1885-29-6 anthranilic acid nitrile 
• 394-47-8 2-fluorobenzonitrile 
• 55165-45-2 2-cyano-benzenediazonium tetrafluoroborate 

Downstream Products

• 1262111-22-7 3,4-dihydro-4-imino-3-propyl-1,2,3-benzotriazine 
• 1885-29-6 anthranilic acid nitrile 
• 1262111-34-1 1-(2-cyanophenyl)-3-(2-thienyl)triaz-2-ene 
• 955-88-4 1-(2-cyanophenyl)-3-phenyltriaz-2-ene 
• 1262111-23-8 3-allyl-3,4-dihydro-4-imino-1,2,3-benzotriazine 
• 1562441-39-7 C₂₅H₂₇N₅O₃ 
• 34913-35-4 2-Cyano-2'.4'.6'-trimethoxydiphenylamin 
• 31162-13-7 2-azidobenzoic acid 

Relevant articles and documents

2-((1-Phenyl-1H-1,2,3-triazol-4-yl)methyl)-2-azabicyclo[3.2.1]octan-3-one derivatives: Simplification and modification of aconitine scaffold for the discovery of novel anticancer agents

The molecular chaperone heat shock protein 90 (Hsp90) is a promising target for cancer therapy. Natural product aconitine is a potential Hsp90 inhibitor reported in our previous work. In this study, we designed and synthesized a series of 2-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)-2-azabicyclo[3.2.1]octan-3-one derivatives as potent Hsp90 inhibitors by simplifying and modifying aconitine scaffold. Among these compounds, 14t exhibited an excellent antiproliferative activity against LoVo cells with an IC50 value of 0.02 μM and a significant Hsp90α inhibitory activity with an IC50 value of 0.71 nM. Molecular docking studies provided a rational binding model of 14t in complex with Hsp90α. The following cell cycle and apoptosis assays revealed that compound 14t could arrest cell cycle at G1/S phase and induce cell apoptosis via up-regulation of bax and cleaved-caspase 3 protein expressions while inhibiting the expressions of bcl-2. Moreover, 14t could inhibit cell migration in LoVo and SW620 cell lines. Consistent with in vitro results, 14t significantly repressed tumor growth in the SW620 xenograft mouse model.

Design and synthesis of novel diosgenin-triazole hybrids targeting inflammation as potential neuroprotective agents

Alzheimer's disease is a progressive neurodegenerative disease, and its incidence is expected to increase as the global population ages. Recent studies provide increasing evidence that inflammation plays a key role in the pathogenesis and progression of AD. Diosgenin, an active ingredient in Dioscorea nipponica Makino, is a promising bioactive lead compound in the treatment of Alzheimer's disease, which exhibited anti-inflammatory activity. To search for more efficient anti-Alzheimer agents, a series of novel diosgenin-triazolyl hybrids were designed, synthesized, and their neuroprotective effects against oxygen-glucose deprivation-induced neurotoxicity and LPS-induced NO production were evaluated. Most of these new hybrids displayed better activities than DIO. In particular, the promising compound L6 not only demonstrated an excellent neuroprotective effect but also showed the best anti-inflammatory activity. The structure-activity relationship study illustrated that the introduction of benzyl or phenyl triazole did improve the activity, and the introduction of benzyl triazole was better than that of phenyl triazole. The results we obtained showed that the diosgenin skeleton could be a promising structural template for the development of new anti-Alzheimer drug candidates, and compound L6 has the potential to be an important lead compound for further research.

Design, synthesis and biological evaluation of erythrina derivatives bearing a 1,2,3-triazole moiety as PARP-1 inhibitors

Inhibitors of poly (ADP-ribose) polymerase-1 (PARP-1) have shown to be promising in clinical trials against cancer, and many researchers are interested in the development of new PARP-1 inhibitors. Herein, we designed and synthesized 44 novel erythrina derivatives bearing a 1,2,3-triazole moiety as PARP-1 inhibitors. MTT assay results indicated that compound 10b had the most potent anti-proliferative activity against A549 cells among five cancer cells. The enzyme inhibitory activity in vitro of compound 10b was also significantly better than rucaparib. Furthermore, the selectivity index of compound 10b was higher than rucaparib for lung cancer cells. Flow cytometry analysis showed that compound 10b induced apoptosis of A549 cells by the mitochondrial pathway. Western blot analysis indicated that compound 10b was able to inhibit the biosynthesis of PAR effectively, and it was more potent than rucaparib. Also, compound 10b was able to up-regulate the ratio of bax/bcl-2, activate caspase-3, and ultimately induced apoptosis of A549 cells. The combined results revealed that the discovery of novel non-amide based PARP-1 inhibitors have great research significance and provide a better choice for the future development of drugs.